Real-World Experience with Subcutaneous Infliximab: Broadening Treatment Strategies for Inflammatory Bowel Disease

The authors provide a comprehensive overview of available clinical trials and real-world data for infliximab (IFX) subcutaneous (SC) treatment of inflammatory bowel disease, focusing on the potential benefits of switching from IFX intravenous to IFX SC.